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SINGLE-CENTER OUTCOMES OF RENAL TRANSPLANTATION IN 
PATIENTS WITH AL AMYLOIDOSIS 
AMANDA T. WIEST 
ABSTRACT 
 AL amyloidosis is a relatively rare but deadly systemic disease that is 
characterized by the deposition of clonal immunoglobulins into many organs, resulting in 
organ dysfunction. Amyloid deposition in the kidneys is the highest cause of morbidity in 
this subset of patients while amyloid deposition in the heart remains the largest cause of 
mortality. Most patients diagnosed with AL amyloidosis will end up with renal 
dysfunction that will progress to ESRD, requiring treatment with dialysis if not treated. 
Advancements in treatment for AL amyloidosis in recent years, specifically the use of 
high dose melphalan followed by stem cell transplantation, has drastically improved the 
survival of these patients. As a result, more patients are living with the consequences of 
irreversible organ damage. Many studies have demonstrated that renal transplantation is 
associated with improved overall survival and quality of life when compared to dialysis 
for treatment of ESRD for any indication. However, renal transplantation for ESRD in 
patients with AL amyloidosis has not been considered to be feasible due to the risks of 
disease relapse and graft failure. Therefore, renal transplantation for patients with AL 
amyloidosis is not routinely considered in most medical centers. A few multidisciplinary 
centers have demonstrated the feasibility of renal transplantation with improved overall 
survival and low rates of graft failure. The proposed retrospective analysis of patients 
undergoing renal transplantation for AL amyloidosis vs. other indications is suspected to 
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demonstrate a 25 percent difference in median graft survival between the two groups, 
thus showing that patients with end stage renal disease (ESRD) secondary to AL 
amyloidosis should be given the same consideration for renal transplantation as patients 
with ESRD secondary to other causes.  
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INTRODUCTION 
Background 
Immunoglobulin light-chain (AL) amyloidosis is a lethal hematologic disorder with a 
median survival of approximately 13 months from diagnosis if left untreated.1 Although 
it is a lethal disorder, AL amyloidosis is relatively uncommon. The true incidence of AL 
amyloidosis is unknown, as many patients will die from the disease prior to diagnosis. 
AL amyloidosis, previously called primary amyloidosis, is the most common form of 
amyloidosis, leading to deposition of insoluble immunoglobulin light chain amyloid 
fibrils into organs and tissues throughout the body. Due to this widespread deposition and 
resultant organ failure, the main goals of treatment are to reduce the amount of amyloid 
produced and to reverse subsequent organ dysfunction. The organs most commonly 
affected by AL amyloidosis are the heart and kidneys, which are the main contributors to 
the significant morbidity and mortality associated with the disease. Prior to the use of 
novel chemotherapeutic agents in addition to stem cell transplantation, 1-year survival for 
AL patients was only 51% while 5 and 10-year survival were 16 and 5%, respectively.1  
Despite advancements in treatment options for AL amyloidosis, many patients 
still progress to organ failure and have poor overall survival. While some organ 
dysfunction in these patients can be reversible with treatment, it is exceedingly rare for a 
patient who ultimately requires dialysis due to amyloid-induced organ damage to be able 
to come off of dialysis. Furthermore, some patients with advanced cardiac amyloidosis 
cannot tolerate the rigorous treatment necessary for disease regression without first 
undergoing cardiac transplantation. A multidisciplinary approach is helpful for achieving 
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the best outcomes for these patients due to the systemic nature of the disease. 
Furthermore, only a handful of medical centers have published data regarding their 
experience with organ transplantation in this subset of patients. 
Statement of the Problem 
Many medical institutions do not offer solid organ transplantation as a treatment option 
for organ failure secondary to AL amyloidosis. This reluctance is primarily because of 
the concern for recurrent amyloid deposition in the newly transplanted graft. In addition, 
treatment of amyloidosis that has relapsed after organ transplantation may interfere with 
graft acceptance, precipitating rejection. Of the centers that do offer organ 
transplantation, little data has been presented regarding overall outcomes for patients 
following organ transplantation, including overall survival and rates of recurrence.  
Hypothesis 
Patients with end stage renal disease secondary to AL amyloidosis who undergo renal 
transplantation have a 25 percent difference in median graft survival when compared to 
patients who receive renal transplantation for other more common indications. 
Objectives and specific aims 
The primary goal of this study is to quantify median graft survival of patients with AL 
amyloidosis who undergo renal transplantation compared to patients receiving renal 
transplantation secondary to other more common indications. The secondary aim of this 
study is to identify AL amyloidosis recurrence rates among patients who have had renal 
transplantation. 
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REVIEW OF THE LITERATURE 
Overview 
Amyloid light-chain (AL) amyloidosis is a hematologic disease caused by misfolding of 
immunoglobulin light chains, which subsequently build up and deposit into various 
organs, leading to cytotoxicity and organ damage. AL amyloidosis is a life-threatening 
disorder that has a median survival of 1 to 2 years if left untreated.2 Furthermore, almost 
a third of all patients diagnosed with AL amyloidosis expire within 3 to 6 months of the 
initial diagnosis due to late diagnosis and associated severe cardiac pathology.3,4 In the 
United States, the incidence of AL amyloidosis is approximately 6 to 10 cases per million 
person-years, which has shown to be consistent over the last few decades upon analysis 
of referral data.1 AL amyloidosis occurs primarily in older adults with the median age of 
64 years at diagnosis, with a male predominance of 65 to 70%.1 AL amyloidosis seems to 
be nondiscriminatory and occurs in patients of all races and locations, the extent of which 
has yet to be studied. 
AL amyloidosis arises from an underlying plasma cell disorder or dyscrasia, 
where amyloidogenic immunoglobulin light chains are produced by monoclonal plasma 
cells. All systemic amyloidoses that result in the production of monoclonal fibrils, 
regardless of the underlying plasma cell disorder, are classified as AL amyloidosis. While 
human adults normally have a kappa to lambda chain immunoglobulin predominance of 
approximately 2:1, fibrils found in AL amyloidosis are four times more often to arise 
from lambda light chains.2,3 Other plasma cell dyscrasias such as multiple myeloma 
(MM) or monoclonal gammopathy of unknown significance (MGUS) are more often 
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associated with fibrils consisting of kappa light chains.2 This is significant as lambda 
light chains have a stronger potential to promote fibrillogenesis than kappa light chains, 
thus leading to excessive amyloid fibril production.2 Pathogenic plasma cells result from 
marked mutations in the variable regions of light chains, likely a result of antigen-driven 
selection and hypermutation occurring prior to migration to the bone marrow.2 
Other factors that contribute to the pathogenesis of AL include post-translational 
modifications, matrix components, extracellular chaperones, and host factors.2 Post-
translational modifications that have been shown to be associated with fibrillogenesis 
include glycosylation, which can increase the binding strength of certain sites on the 
protein or protect areas from protease degradation, as well as cysteinylation, proteolysis, 
and cysteinylation, most of which result in protein destabilization.2 Proteolysis may 
contribute to the light chain fragments often found in amyloid fibrils, however there is 
debate as to whether the fragments could also be a result of aberrant protein synthesis.2 
As the N-terminus of the fibril was most often seen, many researches had proposed that 
the C-terminal fibril fragment had to be cleaved in order to promote fibrillogenesis.5 With 
the utilization of mass spectrometry however, many full-length light chains have been 
observed in the amyloid fibrils deposited on tissues following tissue biopsy, which is 
suggestive that full-length light chains contribute more to the pathogenesis of AL 
amyloidosis as they were more likely to aggregate than light chain fragments.2 
There have been 31 extracellular amyloid fibril proteins identified in humans with 
the likelihood that more will be identified as technological advancements are made.3 All 
of these proteins are similar in their composition, with all amyloid fibrils having a 
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diameter of 7-13 nm, arranged in sheets of anti-parallel beta-strands.3 The matrix 
components of amyloid fibrils also include non-fibrillary constituents such as 
apolipoprotein E (ApoE), glycosaminoglycans (GAGs) including heparin sulfate, 
dermatan sulfate, and chondroitin sulfate, as well as serum amyloid P component (SAP) 
which makes up the amyloid fibril core.2,3 Extracellular chaperones that co-localize with 
amyloid deposits include clusterin, haptoglobin, α2-macroglobulin, and casein, which 
play roles in both fibrillogenesis as well as inhibition of fibrillogenesis.2 
As amyloidosis is a systemic disease, its clinical features are diverse and 
nonspecific to a particular type of amyloidosis, subsequently leading to delays in 
diagnosis. Patients with AL can present with either one organ system affected or with 
extensive multi-system damage, usually with one organ predominantly affected. Signs 
and symptoms leading to suspicion of AL amyloidosis include nephrotic range 
proteinuria, unexplained heart failure, edema, hepatosplenomegaly, and carpal tunnel 
syndrome, with renal involvement being asymptomatic until advanced disease is present.3 
While kidney involvement is the most common finding in patients with AL amyloidosis, 
it is cardiac involvement that is the leading cause of morbidity and mortality.6 Cardiac 
involvement typically presents as restrictive cardiomyopathy, with edema, jugular venous 
distension, congestive hepatomegaly, and evidence of right ventricular failure.3 In vitro 
evidence suggests that AL amyloid has increased myocardial cell toxicity when 
compared to other types of amyloid protein, which supports AL amyloidosis being a 
particularly cardiotoxic disease.7,8 
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Approximately 1 out of 5 patients with AL amyloidosis will experience peripheral 
neuropathy at presentation, with pain and sensitivity to heat or cold.3 Symptoms 
including postural hypotension, early satiety, diarrhea, constipation, or impotence in men 
can result from autonomic neuropathy.3 Unique to AL amyloidosis is the involvement of 
soft tissues, with patients presenting with macroglossia (in less than a third of patients), 
salivary gland enlargement, muscular pseudohypertrophy, and submandibular soft-tissue 
infiltration.3 Patients presenting with bone pain, bony lytic lesions, or hypercalcemia can 
suggest a diagnosis of AL amyloidosis in combination with multiple myeloma.9 	
Diagnosis of amyloidosis depends on confirmation of amyloid deposition, fibril 
type, underlying disorder, and severity of organ involvement. In systemic amyloidoses, 
amyloid deposits can be found in abdominal fat, making abdominal fat biopsy via fine 
needle aspiration a great alternative to organ biopsy when a systemic amyloidosis is 
suspected.6,10 The absence of amyloid in abdominal fat however does not exclude a 
diagnosis of amyloidosis.3 The gold standard test for determining the presence of amyloid 
is the characteristic apple-green birefringence with Congo red stain when examined with 
polarized light microscopy. 	
Tests to assess organ function are important for staging of the disease, with 
assessment of cardiac function being the primary modality for staging (see Table 1). 
Cardiac function can be assessed via echocardiogram, serum cardiac enzymes such as 
troponin, and N-terminal pro-brain natriuretic peptide (NT-pro BNP). Tests to assess 
renal function include serum creatinine, estimated glomerular filtration rate (eGFR), and 
24-hour proteinuria. Liver function can be assessed with liver function tests (LFTs), 
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including alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (ALP), albumin, bilirubin, and clotting factors.  
A highly specific test for diagnosis of cardiac amyloidosis is cardiac magnetic 
resonance imagine (MRI). Furthermore, cardiac MRI gives additional information 
regarding left ventricular mass and cardiac wall thickness.3 Amyloid load in the heart can 
be assessed using equilibrium MRI, which measures the myocardial interstitial volume 
fraction, a level that is greatly increased in amyloidosis.3  
Table 1: Staging of Cardiac AL amyloidosis by cardiac biomarkers, adapted from 
Gertz and Wechalekar et al.6,11  
Stage Description Mean Survival (in 
months) 
I Normal NT-ProBNP, 
Troponin, and iFLC <500 
mg/L 
94.1 
II Abnormal NT-ProBNP, 
normal Trop, and iFLC 
<500mg/L 
40.3 
III Normal Troponin and iFLC 
>500mg/L 
14.0 
IV High Troponin 5.8 
 
It is very important to differentiate the type of amyloidosis as only those 
associated with plasma cell disorders can be treated with chemotherapeutic agents. 
Clinical presentation, family history, biochemical evaluation, genetic sequencing, and 
immunohistochemistry can aid in the determination of amyloid fibril type.12 Amyloid 
fibril type can be determined using mass spectrometric analysis of the amyloid deposits, 
which is necessary to guide treatment. For rare cases of amyloidosis in which it is 
difficult to differentiate type via conventional staining methods, the new technique of 
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laser microdissection combined with mass spectrometry (LMD/MS) has been shown to 
be a sensitive test for typing.13 Diagnosis of AL amyloidosis then depends on 
identification of an underlying plasma cell dyscrasia, which can be done with serum and 
urine immunofixation electrophoresis (SIFE) and measuring serum free light chain (FLC) 
levels to identify monoclonal protein.3 Identification of malignant plasma cells can be 
achieved by observing the expression of certain cell surface proteins. For example, 
CD19, CD27, CD38, and CD45, tend to be expressed less in abnormal plasma cells while 
CD28, CD33, and CD56 tend to have increased expression plasma cell dyscrasias.2 SAP 
scintography can be used to monitor amyloid levels in various tissues including the 
kidneys, liver, spleen, and adrenal glands, which is helpful to monitor progression or 
regression of disease.3  
The leading cause of morbidity in patients with AL amyloidosis is the progression 
to end stage renal disease (ESRD), which is more likely to occur in patients who initially 
present with advanced renal impairment.4,14 Studies have demonstrated that patients 
presenting with lambda light chain amyloid were more likely to have renal impairment 
and increased proteinuria than patients with kappa light chain amyloid.15 Light chain 
induced renal impairment is predominantly caused by deposition of amyloid light chains 
into the glomeruli where they are taken up by mesangial cells and transported to mature 
lysosomes.2 Amyloid fibrils are then formed and expelled into the extracellular matrix. 
As a result of this process, mesangial cells are transformed from smooth muscle cells into 
lysosome-accumulating macrophages.2 Research has shown that proteolytic pathways 
activated by AL amyloid fibrils in the kidney leads to destruction of the extracellular 
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matrix and makes the resultant kidney damage more difficult to reverse.4 Amyloid fibrils 
are also known to deposit into the glomerular basement membranes and blood vessel 
walls.16  
At the time of diagnosis, 70% of patients with AL already have renal 
involvement.14 Approximately 73% of patients will have proteinuria, 28% will have 
nephrotic syndrome, and half of patients will have renal insufficiency at the time of 
diagnosis.17 Poor prognostic factors for renal outcomes in AL patients include low GFR 
and heavy proteinuria at diagnosis.18 A large study of German and Italian patients (from 
Heidelberg, Germany and Pavia, Italy respectively) with AL amyloidosis revealed that 
those with stage III renal disease defined by both proteinuria >5 g/d and eGFR < 50 
mL/min/1.732 at the time of initial diagnosis were at a 60% increased risk of progression 
to ESRD while patients with stage II renal disease defined by having only one of the 
above risk factors had only a 7% increased risk.19 Patients with stage I renal disease 
without proteinuria or abnormalities in eGFR at the time of diagnosis did not progress to 
ESRD.19  
As the above study was performed on patients newly diagnosed with AL 
amyloidosis and did not differentiate patients based on treatment modality, the 
Amyloidosis Center at BUSM performed a similar study looking only at patients who 
received the gold standard high dose melphalan and stem cell transplantation 
(HDM/SCT). The study included 421 patients, 78% of which had AL amyloidosis with 
renal involvement and an overall median survival of 13.4 years.20 Similar to the above 
study, the Amyloidosis Center also found that independent determinants for progression 
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to ESRD were proteinuria > 5 g/24h and eGFR < 50 mL/min/1.73m2.20 They ultimately 
found that patients with stage II renal disease had 2.5 times risk of progression to ESRD 
when compared to patients with stage I renal disease, and patients with stage III renal 
disease having a 4.5 times increased risk.20 (See Table 2) This study ultimately 
demonstrates that patients specifically receiving HDM/SCT had better overall survival as 
well as renal survival than in previous studies where treatment modalities were 
undifferentiated. Both studies revealed no significant difference in overall survival 
between patients in any stage of renal disease.20  
Table 2: Staging of Renal Amyloidosis and Risk of Progression to ESRD following 
HDM/SCT (adapted from Palladini et al, Havasi et al)19,20 
Stage Description Progression to ESRD 
I eGFR ≥ 50 mL/min/1.73m2 
and < 5 g/24h proteinuria 
No risk 
II Either eGFR < 50 
mL/min/1.73m2 or ≥ 5 
g/24h proteinuria 
2.5 times increased risk 
III eGFR < 50 mL/min/1.73m2 
and ≥ 5 g/24h proteinuria 
4.5 times increased risk 
 
A study performed by the Mayo Clinic found that a greater than 95% reduction in 
proteinuria in the span of 1 year was associated with longer overall survival and that rises 
in serum creatinine were not associated with decreased overall survival.19 The AL 
Amyloidosis Chemotherapy (ALchemy) study performed from 2009 to 2015 revealed 
that patients had significantly improved prolonged time to dialysis as well as overall 
survival when they achieved > 90% or more suppression of the difference between 
involved and uninvolved free light chain (dFLC) within 3 months of baseline.14 This 
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study also demonstrated that delay of achieving the target after 3 months was associated 
with worse renal outcomes, making it apparent that the speed and magnitude at which 
treatment is administered is critical for preserving renal function and improving overall 
survival, even in patients with advanced CKD at the time of initial diagnosis.14  
The importance of monitoring the degree of cardiac damage in patients with AL 
amyloidosis cannot be overstated as it is critical for risk stratification, prognostication, 
and guiding treatment.21 Poor prognostic factors include severe postural hypotension, 
poor performance status, low systolic blood pressure (<100 mm Hg), or New York Heart 
Association (NYHA) functional class 3 or higher functional status (marked limitation in 
activity secondary to symptoms, even during less-than-ordinary activity, only 
comfortable at rest, or severe limitations with symptoms occurring even with rest).6 
Cardiac biomarkers have been used to establish the Mayo Clinic staging system for AL 
amyloidosis. In their study, the Mayo Clinic found that patients with stage III disease 
have a median survival of 7 to 8 months while those with stage IIIb disease have a 
median survival of 3 months.22  
All current chemotherapeutic treatment for amyloidosis involves an attempt to 
reduce the amount of precursor proteins available to synthesize amyloid fibrils in an 
attempt to lessen the degree of end-organ damage. Patients with AL amyloidosis who 
have the best outcomes are those who achieve a complete response (CR) or very good 
partial response (VGPR), where CR is defined as having no detectable monoclonal 
immunoglobulin band on SIFE and normal serum free light chains (FLC) and VGPR with 
a dFLC < 40 mg/L.6 (see Table 2) Measuring cardiac response is a good way to monitor 
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treatment efficacy for AL amyloidosis, where the goal is to observe a 30% or 300 ng/L 
decrease in serum NT-proBNP.23 The main treatment goal for AL amyloidosis has been 
to target the underlying plasma cell dyscrasia with chemotherapeutic agents and 
autologous stem cell transplantation (ASCT). As treatments for plasma cell dyscrasias 
have improved over the last decade, specifically treatments for multiple myeloma, which 
is seen comorbidly in 10-15% of patients with AL amyloidosis, median survival for these 
patients has almost doubled.3,24  
Table 3: Response to treatment criteria (adapted from Havasi and Stern)25 
Response Criteria 
No Response < 50% reduction in monoclonal protein in serum 
Partial Response (PR) > 50% reduction in monoclonal protein in serum 
Very Good Partial Response (VGPR) Partial response with dFLC < 40 mg/L 
Complete Response (CR) Absence of monoclonal protein on SIFE, 
Normal serum FLC ratio, 
< 5% plasma cells without clonal predominance 
by immunohistochemistry on bone marrow 
biopsy 
 
Patients with AL amyloidosis are classified into three main groups: low, 
intermediate, or high risk. Low risk patients make up approximately 15-20% of all 
patients with AL amyloidosis.3 Patients considered to be low risk are those with excellent 
performance status, NT-proBNP < 5000 ng/mL, cardiac troponin T (cTnT) < 0.06 ng/mL, 
good renal function, and patients without significant pleural effusions, gastrointestinal 
bleeding secondary to amyloidosis, or autonomic neuropathy.3 These patients are most 
often treated with high-dose melphalan followed by ASCT with studies showing VGPR 
in 56% and CR in 44% of patients.26 As a result of the excellent clonal response rates, 
three quarters of low-risk patients receiving high-dose melphalan followed by ASCT had 
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improved organ function, greater than 8-year progression free survival, and greater than 
10-year median overall survival.27 Multiple studies have demonstrated the use of 
bortezomib, a proteasome inhibitor that was initially used as a treatment for multiple 
myeloma, as an induction agent in patients with AL amyloidosis resulted in VGPR in 
greater than 90% of patients.28,29  
Intermediate risk patients make up the majority of patients with AL amyloidosis 
and often receive treatment with combination chemotherapy. Standard of care regimens 
for this group include oral melphalan with dexamethasone (MDex) as well as 
cyclophosphamide, thalidomide, and dexamethasone (CTDa), with studies revealing 
hematologic response rates of 65-75% after 3-4 months of treatment.30,31 Use of 
bortezomib as a single agent or in combination with dexamethasone has been used in this 
subset of patients as well as patients with relapsed disease.3 The treatment modality of 
choice for most intermediate-risk AL amyloidosis is the combination regimen of 
bortezomib cyclophosphamide, and dexamethasone (CyBorD), which multiple studies 
reveal early response rates in greater than 90% of patients as well as VGPR or CR in 60% 
of patients.32,33  
Patients with high-risk AL amyloidosis usually begin treatment with bortezomib-
based combination regimens due to the need for rapid response, however there has been 
no regimen that has proven superior in this subset of patients.3 Newer 
immunomodulatory agents such as lenalidomide and pomalidomide have been useful in 
patients with refractory or relapsed disease after previous treatment with proteasome 
inhibitors.3  
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Existing research 
As previous studies mentioned independent determinants for progression to ESRD 
(Palladini et al, Havasi et al), Gertz et al. found that 24-hour urine protein loss and 
creatinine levels at presentation were the best predictors of the eventual need for 
dialysis.15 Patients with AL amyloidosis that were treated at BUSM specifically with 
HDM/SCT and ultimately required dialysis had a much better median survival of 39 
months from the initiation of dialysis when compared to patients who did not achieve 
disease remission with HDM/SCT.20 These results were similar to the median survivals 
found in the studies performed by Palladini et al, which had a median survival of 39 
months following initiation of dialysis in its Pavia, Italy cohort and a 24 month median 
survival in the Heidelberg, Germany cohort.19,20 Although these studies demonstrated that 
the regimen of HDM/SCT improved overall outcomes following the initiation of dialysis, 
it was also noted that dialysis remains a major cause of mortality in patients with AL 
amyloidosis.20  
 Renal transplantation is utilized as a treatment modality for patients with ESRD 
secondary to AL amyloidosis with the aim of preventing the need for dialysis and to 
improve quality of life. The World Health Organization (WHO) found that renal 
transplantation made up 67% of all organ transplants worldwide.34 In a systematic review 
of renal transplantation for any indication, with meta-regression analysis, Tonelli et al 
found that when compared with dialysis, renal transplantation was associated with 
reduced risk of mortality and improved quality of life, with the vast majority of studies 
included in the review significantly favoring transplantation over hemodialysis.35 
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Because of this, renal transplantation is commonly sought after in patients with various 
diseases causing ESRD. There is unfortunately a very limited supply of both living and 
deceased donor kidneys available for the numerous amounts of patients who need them. 
The WHO reports that 59% of all donor kidneys come from deceased donors.34 The 
shortage of donors available prolongs waiting time for transplantation and often causes 
patients to require dialysis. Furthermore, there is no absolute guarantee that the new graft 
will not be rejected. For this reason, selection of which patients are able to receive a 
donor kidney is a rigorous process that involves significant evaluation. Patients with AL 
amyloidosis are not readily considered for transplantation due to the underlying 
malignancy as well as lack of data regarding outcomes for both graft and overall survival. 
 It is important to appreciate graft survival in patients undergoing renal 
transplantation as the benefit of having this major surgery only lasts as long as the graft 
that is transplanted survives.36 For renal transplantation across all indications, first-year 
survival has improved greatly over the last few decades, with greater than 90% graft 
survival rates.37 A retrospective analysis performed by Lamb et al revealed improvements 
in graft survival, with a graft half-life of 6.6 years in 1989 to a graft half-life of 8.8 years 
in 2005 for deceased-donor allografts.37 They also demonstrated no significant change in 
graft half-life for patients having living-donor allografts, with a graft half-life of 11.4 
years in 1989 and 11.9 years in 2005.37 It should also be noted that patients undergoing 
living-donor allograft transplantation tend to have better graft survival than patients 
having deceased-donor kidneys. 
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Renal transplantation should be considered carefully in patients with AL 
amyloidosis as it has been established that a major complication of transplantation is the 
development of malignancy due to the need for immunosuppression to prevent graft 
rejection. Renal transplants performed prior to the advancement of AL treatment often 
had poor outcomes, with disease recurrence, graft failure, and early loss of life.17 The 
pathogenesis of malignancy following renal transplantation is due to the derangement of 
the immune surveillance mechanisms responsible for prevention of malignancies.38 
Treatment of malignancies that arise following successful kidney transplantation then 
becomes very difficulty as it involves reducing the amount of overall 
immunosuppression, thus putting the graft at risk of acute rejection.38  
Renal transplantation has been discouraged in the past for patients diagnosed with 
plasma cell dyscrasias not only due to the possibility of progressing neoplasia, but also 
the high infection rates and sepsis that can accompany the use of immunosuppressive 
agents.16 It has also been noted that immunosuppressive therapy can cause the 
overexpression of paraproteins that can also negatively affect the new graft.16 Kidney 
transplantation has been made possible in this subset of patients due to the use of newer 
chemotherapeutic treatments followed by hematopoietic stem cell transplantation (HCT) 
to treat plasma cell dyscrasias. For example, studies have shown that patients with ESRD 
secondary to multiple myeloma who undergo kidney transplantation have higher overall 
survival rates than patients who are managed with dialysis.16  
 Consideration for renal transplantation as a treatment for ESRD secondary to any 
disease is given to patients with stage 5 kidney disease (eGFR < 15 ml/min/1.73m2) who 
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do not have contraindications to either major surgery or immunosuppression.39 Patients 
with eGFR > 15 ml/min/1.73m2 may also be considered for transplantation if significant 
uremic symptoms are present.39 Current recommendations for determining eligibility for 
renal transplantation in patients with AL amyloidosis rely on a documented durable 
hematologic response following stem cell transplantation. Patients under consideration 
for renal transplantation should have at least a partial response (PR) (Table 2) that is 
maintained for at least 12 months following stem cell transplantation without any 
additional treatment.25  
It was initially recommended that patients achieve at least VGPR prior to 
consideration, however a study performed in the UK by Pinney et al published in 2013, 
although underpowered with 25 patients, found no significant difference in renal allograft 
survival between patients who underwent renal transplantation after achieving CR vs. 
PR.40 The same study demonstrated that patients who underwent renal transplantation 
after having no response (NR) to treatment had an overall graft survival of 5.3 years 
when compared to 8.9 years in patients who achieved either CR or PR.40 Differentiation 
of median graft survival was not made between patients who achieved CR vs. PR in this 
study. The overall results of their study found a median graft survival of 5.8 years 
between all three response groups, with 74% 5-year graft survival, 25% 10-year graft 
survival, and median overall survival of 89.0 months following renal transplantation.40,41 
They also noted that while 7 out of 25 grafts had evidence of amyloid deposition at a 
median of 5.9 years following transplantation, there was no evidence of graft failure.40  
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 Another study of 19 patients at the Mayo Clinic published in 2011 compared the 
results of AL patients who underwent renal transplantation in three different treatment 
arms: renal transplant followed by ASCT, ASCT followed by renal transplant, and renal 
transplant following achievement of CR following nonmyeloablative therapy.17 Although 
the median graft survival of each treatment group was not explicitly stated in this study, 
they reported no difference in overall survival or graft survival between the three groups, 
with recurrence of amyloidosis documented in 2 patients and evidence of cellular 
rejection documented in 5 patients.17  
 Further research must be done in order to see if renal transplantation outcomes in 
patients with AL amyloidosis are similar to that of patients undergoing renal 
transplantation for other causes of ESRD. The data that has been previously published for 
renal transplantation for AL amyloidosis has not been previously compared to a control 
group. This study, if successful, will demonstrate that patients with AL amyloidosis 
should be given the same consideration for renal transplantation as patients with other 
causes of ESRD. 
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METHODS 
Study design 
A retrospective, single-center, cohort study will be performed to compare overall median 
survival and graft survival in a finite population of patients with AL amyloidosis who 
underwent renal transplantation vs. patients who underwent renal transplantation 
secondary to a more common indication, such as diabetic nephropathy or lupus nephritis. 
Data will be obtained using records from the Amyloidosis Center at Boston University 
School of Medicine as well as the Nephrology department at Boston Medical Center. 
Electronic medical records from Epic and Logician, as well as hard copy records from the 
Amyloidosis Center will be reviewed. 
Study population and sampling 
Patients of all ages diagnosed with AL amyloidosis via biopsy who were deemed eligible 
for renal transplantation by the Amyloidosis Center at Boston University School of 
Medicine will be included in the group A cohort of the study. Patients in the same age 
and sex distribution as patients in group A who underwent renal transplantation for any 
other indication will be included in the group B cohort. Patients in group A who are 
deemed eligible for transplantation will have had a durable complete response (CR) or 
very good partial response (VGPR), that is a response maintained for at least 12 months, 
without any additional treatment prior to the consideration of transplantation, irrespective 
of the treatment used to achieve the response (chemotherapy followed by SCT or 
nonmyeloablative treatment).25 Data previously acquired had the earliest renal 
transplantation dating back to 1989. Therefore, patients who were able to undergo renal 
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transplantation between the years of 1989 and 2016 with either living and deceased donor 
kidneys will be included. All inclusion and exclusion criteria are discussed in Table 4. 
The amount of patients who meet inclusion criteria for group A has already been 
established, with 35 patients being identified. Previous studies have demonstrated median 
graft survivals of 8.9 years in patients with AL amyloidosis who underwent renal 
transplantation after achievement of CR or PR and 11.9 years for patients who underwent 
renal transplantation for any indication.37,40 As most patients who undergo renal 
transplantation receive a living-donor graft, using living-donor median graft survival for 
patients receiving renal transplantation for any indication will be most accurate for 
calculating effect size. Using a sample size of 35 with an effect size of 0.25 yields a 
power of 0.2316 at a significance level of 0.5.42 However, a traditional sample size 
calculation is not feasible given the nature of a single-center study with a limited amount 
of patients meeting inclusion criteria upon chart review. A sample size of convenience 
will therefore be utilized in the statistical analysis of this study. 
Table 4: Group A Study Inclusion and Exclusion Criteria 
Inclusion Exclusion 
1. All patients regardless of age with 
biopsy proven AL amyloidosis who 
had achieved at least VGPR 
following chemotherapy and 
ASCT, maintained for at least 12 
months without any additional 
treatment. 
2. Patients with AL amyloidosis who 
are otherwise in good health and are 
eligible for renal transplantation. 
 
1. Patients with non-AL amyloidosis 
or monoclonal immunoglobulin 
deposition disease. 
2. Patients lost to follow up or with 
insufficient information in medical 
records. 
3. Patients with severe illness that 
would otherwise preclude them 
from renal transplantation.43 
4. Patients with contraindications to 
immunosuppressive therapy.39 
5. Patients with social issues that 
prevent compliance with vigorous 
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post-transplantation treatment 
regimen.43 
 
Treatment  
Patients eligible for inclusion will be divided into two study arms. Group A will include 
AL patients who were eligible and received renal transplantation while group B will 
include all patients in the same age and gender distribution who underwent renal 
transplantation at BUSM for any other indication. 
Study variables and measures 
The primary outcome of this study will include be median graft survival from date of 
renal transplantation to date of death. Five-year overall and graft survival will also be 
included. Comparisons will be made between groups A and B for both median and graft 
survival. The secondary outcome to be measured for group A only is the median time 
from renal transplantation to disease relapse requiring treatment. Observations will be 
made regarding overall outcomes of patients in group A as well as any possible trends in 
toxicities from salvage therapy for disease relapse following renal transplantation that 
may be unique to patients with AL amyloidosis. 
Recruitment 
Recruitment of group A patients with AL amyloidosis who meet the inclusion criteria, 
whether living or deceased, and received treatment at the Amyloidosis Center at Boston 
University School of Medicine will be included if they previously consented in writing 
for their data to be used for research purposes. A list of patients who received renal 
transplantation at BUSM has previously been compiled with transplant dates ranging 
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from 1989 to 2016. Recruitment of the group B cohort will include EMR diagnosis 
search of “end stage renal disease” or “ESRD” and “renal transplantation” or “kidney 
transplantation.” Patients selected for group B will be in the same age and gender 
distribution as patients in group A. Patients in group B who are deemed eligible but have 
not previously signed agreements to be included in research studies at BUSM will be 
contacted to obtain consent. 
Data collection 
Data extracted from EMR and hard copy medical records from the Amyloidosis Center at 
BUSM for group A will include demographic information such as date of birth and 
gender as well as information regarding disease status including type of amyloid 
diagnosis, date of diagnosis, date of SCT, date of organ transplantation, date of disease 
relapse, date of evidence of graft failure, major complications, date of last follow-up, and 
date of death. Information regarding disease relapse following renal transplantation will 
be collected to aid in future studies of outcomes for salvage therapy. Correspondence 
records from outside facilities that were forwarded to BUSM will also be reviewed for 
pertinent information. (See Appendix 1) 
 Data extraction for group B patients will also include demographic information 
including date of birth and gender as well as information regarding disease status 
including the underlying diagnosis that precipitated renal transplantation, date of 
diagnosis, date of renal transplantation, date of evidence of graft failure, major 
complications, date of last follow-up, and date of death. 
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Data analysis 
Both median graft survival for each treatment group will be calculated in months from 
date of diagnosis to date of death and date of transplantation to death, respectively. These 
results will be analyzed and displayed graphically using Kaplan-Meier survival analysis. 
Comparison of median graft survival in group A vs. group B will be calculated using a t-
test at the 95% confidence level. Descriptive data will be used to characterize 
complication rates including recurrence of AL amyloidosis and any major infections. 
Timeline and resources 
IRB approval was previously obtained for this study and last updated with personnel 
changes on August 1, 2017. Chart review for patients who underwent renal 
transplantation was performed from August 2017 to December 2017. Chart review for 
group B renal transplant patients will be carried out from January 2018 to April 2018. 
Data analysis will be performed in May 2018. The manuscript will be submitted for 
review in June 2018. 
Personnel: 
• Primary investigator at the Amyloidosis Center, Boston University School of 
Medicine 
• Study coordinator 
• Statistician consulting group 
A total budget of $46,000 will be needed to complete this study, with $20,000 allotted for 
the primary investigator, $25,000 for the study coordinator, and $1,000 for the statistician 
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consulting group (rate of $100/hour for 10 hours). Computers for chart review are already 
available for use in the Amyloidosis Center. 
Institutional Review Board 
A proposal for expedited review has been submitted and approved by the Institutional 
Review Board at Boston University School of Medicine, with the latest personnel updates 
approved on August 1, 2017. 
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CONCLUSION 
Discussion 
The notable limitations of this study include the retrospective nature as well as the limited 
number of participants available in group A to make results statistically significant. 
Furthermore, the sample sizes of group A vs. group B are likely to differ as there are 
many more patients who receive renal transplantation secondary to diseases other than 
AL amyloidosis, which would make the group B sample size considerably larger. 
Although trying to mitigate as many differences between groups A and B as possible by 
selecting group B patients in similar age and sex demographics, it should be mentioned as 
a limitation to the study given the difference in disease states. As AL amyloidosis is a 
relatively rare disease, patients come from around the US and even from different 
countries to receive treatment. For this reason, patients receive their initial treatment from 
BUSM and are then lost to follow up, making it hard to compile the relevant data needed 
to complete the study and to maximize sample size. 
 Although not an official aim of the study, it would be interesting to observe 
whether patients with AL amyloidosis who undergo renal transplantation have increased 
rates of malignancy following transplant when compared to patients having nonmalignant 
causes of ESRD.  
Summary 
The overall survival of patients with AL amyloidosis has improved significantly over the 
last few decades due to the use of a multidisciplinary approach as well as advancements 
in chemotherapeutic agents in conjunction with stem cell transplantation. The ability to 
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achieve a durable response via multiple treatment modalities has made it possible to 
preserve organ function by reversing the damage done by amyloid deposition and by 
making it possible for patients to undergo solid organ transplantation with less of a 
concern for rejection or precipitating malignancy. These advancements in treatment have 
led to significant improvement in both overall survival as well as graft survival in patients 
with AL amyloidosis. There are few facilities around the world that offer organ 
transplantation in this subset of patients. Of the facilities that do offer renal 
transplantation for patients with AL amyloidosis, little comparison data exists. Studies 
looking at patients with a different plasma cell dyscrasia, multiple myeloma, that 
underwent renal transplantation for ESRD revealed that patients who underwent renal 
transplantation had better overall survival rates than patients whose ESRD was managed 
with dialysis. These results show promise that the same can be true for patients with AL 
amyloidosis. 
Clinical and/or public health significance 
The relevance of this study is significant due to the amount of patients who have 
associated renal impairment with AL amyloidosis at diagnosis, a significant number of 
who progress to end stage renal disease and ultimately require renal replacement therapy. 
Renal transplantation is an excellent option in these patients as research has shown better 
outcomes in both overall survival as well as quality of life when compared to dialysis. 
The results of this study can demonstrate that patients with AL amyloidosis and ESRD 
have similar outcomes to patients undergoing renal transplantation for ESRD secondary 
to other conditions. This would allow patients with AL amyloidosis to be given the same 
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consideration as other patients who need transplantation due to other causes. 
Furthermore, this study paves the way for additional studies to be completed in series, 
including the use of specific salvage chemotherapeutic agents and whether or not they 
may be associated with acute graft rejection. This becomes relevant as treatment 
advancements are made in as little as every six months, with very little evidence 
presented on their use following organ transplantation. 
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APPENDIX 
Appendix 1 
Data Extraction from Medical Records 
1. Medical Record Number 
2. Patient Initials 
3. Underlying Disease 
4. Date of Diagnosis 
5. Date of SCT (if any) 
6. Date of Renal Transplantation 
7. Date of Evidence of Graft Failure 
8. Date of Recurrence of AL Amyloidosis 
9. Other Major Complications 
10. Date of Last Follow-up 
11. Date of Death 
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